KASL clinical practice guidelines for management of chronic hepatitis B

INTRODUCTION Chronic hepatitis B (CHB) is a major cause of chronic liver diseases in Korea and remains a threat to public health due to its high morbidity and disease-related mortality. Since the latest version of clinical practice guidelines of CHB in 2018 by the Korean Association for the Study of...

Full description

Saved in:
Bibliographic Details
Published inClinical and molecular hepatology Vol. 28; no. 2; pp. 276 - 331
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Association for the Study of the Liver 01.04.2022
The Korean Association for the Study of the Liver
대한간학회
Subjects
Antibodies
Antigens
Antiviral Agents - therapeutic use
chronic hepatitis b
Clinical medicine
Clinical practice guidelines
Committees
disease management
Guideline
Hepatitis B
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Humans
Infections
kasl guidelines
Liver cancer
Liver cirrhosis
Patients
therapeutics
Transplants & implants
treatment
내과학
Treatment
Disease management
Chronic hepatitis B
KASL guidelines
Therapeutics
Online AccessGet full text

Cover

More Information
Summary:INTRODUCTION Chronic hepatitis B (CHB) is a major cause of chronic liver diseases in Korea and remains a threat to public health due to its high morbidity and disease-related mortality. Since the latest version of clinical practice guidelines of CHB in 2018 by the Korean Association for the Study of the Liver (KASL), many studies related to hepatitis B virus (HBV) have been published, raising the need to revise the recommendations reflecting the most up-to-date information on management of CHB. The KASL will continue to update part or all of these guidelines based on publication of new study results. [...]revision of the guidelines is deemed necessary for promoting the health of Korean CHB patients. [...]there can be grey zone in which the features do not correspond to any specific phase. [...]it is often insufficient to determine the clinical stage of infection or to decide antiviral treatment based on a single alanine aminotransferase (ALT) or HBV DNA test (Fig. 1) [1]. The immune-tolerant phase can last for more than three decades in patients infected with HBV genotype C due to late HBeAg seroconversion [8]. [...]many female patients infected with this genotype are in the immune-tolerant phase when they are of childbearing age, which can lead to vertical transmission of
Bibliography:SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
Clinical Practice Guidelines Committee of KASL for the Management of Chronic Hepatitis B: Jeong Won Jang (Committee chair, The Catholic University of Korea), Jun Yong Park (Yonsei University College of Medicine), Jung Hyun Kwon (The Catholic University of Korea), Su Jong Yu (Seoul National University College of Medicine), Wonseok Kang (Sungkyunkwan University School of Medicine), Young Eun Chon (CHA University College of Medicine), Tae Hyung Kim (Korea University College of Medicine), Jonggi Choi (University of Ulsan College of Medicine), Jihyun An (Hanyang University College of Medicine)
Editor: Seung Up Kim, Yonsei University College of Medicine, Korea
ISSN:2287-2728
2287-285X
2287-285X
DOI:10.3350/cmh.2022.0084